Samuel J. Reich

Samuel J. Reich is the current Chairman at SAB Biotherapeutics. Prior to this, they served as the Chief Executive Officer at Big Cypress Acquisition Corp from December 2020 to October 2021. Samuel was also the Executive Chairman at Biscayne Neurotherapeutics from December 2016 to October 2018. Biscayne Pharmaceuticals, Inc. is a privately held biopharmaceutical company discovering and developing novel therapies based on growth hormone-releasing hormone (GHRH) analogs. The company’s technology stems from the discoveries of Dr. Andrew V. Schally, a Nobel laureate and pioneering endocrine drug developer. Biscayne’s lead compounds include GHRH antagonists in development for the treatment of cancer, including castrate-resistant prostate cancer, and GHRH agonists for the repair of cardiac damage in heart disease patients. Prior to their work at Biscayne Neurotherapeutics, Reich served as the Managing Member at The Reich Group and as the Chairman at Insero Health, Inc. from January 2011 to June 2015. Samuel also served as the Executive Vice President at OPKO Health, Inc. from March 2007 to November 2008.

Reich attended Choate Rosemary Hall for their secondary education and then went on to Clark University where they completed their Bachelor of Arts in Molecular Biology. Samuel continued their studies at the University of Pennsylvania School of Medicine, completing their Cellular and Molecular Biology degree.